Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.43 |
| ▸ | HTR3B | O95264 | 3/20 | 0.43 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8274280 | 0.98 | TRPV3 (0.48) | TRPV3PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL4547904 | 0.96 | TRPV3 (0.43) | TRPV3PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL18270122 | 0.92 | HTR3A (0.50) | TRPV3HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23114416 | 0.86 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8274290 | 0.86 | HTR3A (0.62) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL15341818 | 0.84 | HRH3 (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5222665 | 0.84 | HTR3E (0.58) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4547898 | 0.84 | GAA (0.48) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20098858 | 0.82 | ACACB (0.36) | TRPV3PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL23107095 | 0.82 | ACACB (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | TRPV3 2537/4885PDE10A 2719/4885HTR3E 2907/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | TRPV3 170/4885PDE10A 635/4885HTR3E 293/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | TRPV3 170/4885PDE10A 635/4885HTR3E 293/4885 |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV3 3064/4885PDE10A 2000/4885HTR3E 1611/4885 |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | TRPV3 3727/4885PDE10A 2663/4885HTR3E 1627/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | TRPV3 3206/4885PDE10A 3248/4885HTR3E 3566/4885 |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | BAX, BAD, BCL2 | TRPV3 3724/4885PDE10A 3399/4885HTR3E 3567/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | TRPV3 4484/4885PDE10A 2740/4885HTR3E 379/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | TRPV3 3431/4885PDE10A 3777/4885HTR3E 288/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | TRPV3 4678/4885PDE10A 3480/4885HTR3E 2989/4885 |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV3 4510/4885PDE10A 1383/4885HTR3E 3239/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | TRPV3 3724/4885PDE10A 3399/4885HTR3E 3567/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | TRPV3 170/4885PDE10A 635/4885HTR3E 293/4885 |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV3 1966/4885PDE10A 3388/4885HTR3E 2422/4885 |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | TRPV3 3518/4885PDE10A 3024/4885HTR3E 1952/4885 |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV3 3453/4885PDE10A 3545/4885HTR3E 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.